Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 10, 2025 • 3:30 AM ET

Date/Time Source News Release
04/30/2025 07:00 AM EDT GlobeNewswire Larimar Therapeutics Reports First Quarter 2025 Financial Results
03/24/2025 07:00 AM EDT GlobeNewswire Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
03/03/2025 04:05 PM EST GlobeNewswire Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
01/23/2025 04:05 PM EST GlobeNewswire Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia
12/16/2024 07:00 AM EST GlobeNewswire Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
09/19/2024 07:00 AM EDT GlobeNewswire Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
08/27/2024 08:00 AM EDT GlobeNewswire Larimar Therapeutics to Participate in Upcoming Investor Conferences
08/07/2024 07:00 AM EDT GlobeNewswire Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results
05/30/2024 04:05 PM EDT GlobeNewswire Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
05/20/2024 04:05 PM EDT GlobeNewswire Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
Page

Additional News

As of June 10, 2025 • 3:30 AM ET

Date/Time Source News Release
05/08/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, May 8th, 2025
05/08/2025 05:31 AM EDT US Earnings Reports Expected earnings - Larimar Therapeutics Inc.
04/30/2025 08:10 AM EDT SeekingAlpha Larimar Therapeutics GAAP EPS of -$0.46 misses by $0.04
04/04/2025 01:12 PM EDT SeekingAlpha Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts
03/24/2025 07:06 AM EDT SeekingAlpha Larimar Therapeutics GAAP EPS of -$0.45
03/20/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, March 20th, 2025
03/20/2025 05:30 AM EDT US Earnings Reports Expected earnings - Larimar Therapeutics Inc.
03/13/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, March 13th, 2025
03/13/2025 05:31 AM EDT US Earnings Reports Expected earnings - Larimar Therapeutics Inc.
03/02/2025 08:33 AM EST SeekingAlpha Invest In A New Biotech Bull Market With XBI And IBB
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.